{"links":{"html":"https://www.erudio.com/reports/eurtac-nct00446225","json":"https://www.erudio.com/reports/eurtac-nct00446225.json","markdown":"https://www.erudio.com/reports/eurtac-nct00446225.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"eurtac-00446225"}},"request":"https://www.erudio.com/contact?report=eurtac-00446225"},"offer":{"cited_commentary_sources":9,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a licence key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, to join with NPI-keyed systems such as a CRM. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":750,"identity_verified_people":17,"optional":true,"price_per_verified_person_usd":15,"price_usd":255,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One licence key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"eurtac-nct00446225"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the licence key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=eurtac-00446225","people":"Tom and Audun, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/eurtac-nct00446225","renewal":"Subscriptions are prepaid and do not renew automatically.","terms":"https://www.erudio.com/terms"},"size":"focused","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-08T03:47:17.775241Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":1,"discussed":9,"no_commentary_found":0},"aspects":[{"claim_count":14,"coverage":"discussed","id":"A1","source_count":4,"title":"EURTAC's first-line TKI-versus-chemotherapy decision"},{"claim_count":20,"coverage":"discussed","id":"A2","source_count":3,"title":"Molecular work-up before the first-line decision"},{"claim_count":47,"coverage":"discussed","id":"A3","source_count":2,"title":"Alternative first-line regimens and selection for intensification"},{"claim_count":30,"coverage":"discussed","id":"A4","source_count":2,"title":"Prevention, referral and administration burden with the amivantamab alternative"},{"claim_count":11,"coverage":"discussed","id":"A5","source_count":1,"title":"Brain metastases and selective local-treatment roles"},{"claim_count":10,"coverage":"discussed","id":"A6","source_count":1,"title":"Crossover, historical controls and mutation-associated prognosis"},{"claim_count":15,"coverage":"discussed","id":"A7","source_count":2,"title":"Boundary of extrapolation to uncommon sensitizing mutations"},{"claim_count":9,"coverage":"discussed","id":"A8","source_count":3,"title":"European applicability, testing access and historical reimbursement conditions"},{"claim_count":24,"coverage":"discussed","id":"A9","source_count":1,"title":"Population selection, confirmation and retrospective lessons"},{"claim_count":0,"coverage":"assessment_incomplete","id":"A10","source_count":0,"title":"EURTAC-specific molecular follow-up interpretation"}],"counts":{"cited_sources":9,"claims_by_expression_type":{"comparison":25,"experience":10,"interpretation":28,"opinion":38,"primary_context":1,"question":23,"restatement":40,"uncertainty":27,"unspecified":18},"claims_by_kind":{"attributed_opinion":1,"interpretation":19,"limitation":1,"source_observation":189},"evidence_units":99,"findings":9,"people_cited":16,"people_identity_verified":17,"people_total":30,"screened_sources":12,"verified_claims":210},"depth":"thin","depth_rule":"thin if verified claims <30, findings <5, or cited sources <10; rich if verified claims >=100, findings >=8, and cited sources >=30; otherwise standard","findings_index":[{"id":"F1","title":"TKI-first treatment was favored despite the absence of an overall-survival difference at the time"},{"id":"F2","title":"Timely, interpretable genotyping was treated as a prerequisite for safe treatment selection"},{"id":"F3","title":"Modern intensification preferences were conditional, while predictive selection remained unresolved"},{"id":"F4","title":"Supportive care was integral to the amivantamab option, with anticoagulation duration still questioned"},{"id":"F5","title":"CNS control favored systemic treatment first, but selective local-treatment roles were retained"},{"id":"F6","title":"Historical-control questions exposed unresolved disagreement about mutation-associated prognosis"},{"id":"F7","title":"The common-mutation treatment discussion did not translate into a single approach for uncommon sensitizing mutations"},{"id":"F8","title":"European confirmation was viewed as an access-enabling step, not merely replication of Asian findings"},{"id":"F9","title":"Retrospective commentary emphasized population selection and the provisional nature of clinical understanding"}],"medical_affairs_question":"How should scientific exchange explain the rationale for TKI-first sequencing without converting PFS, response or quality-of-life arguments into a demonstrated overall-survival claim?","sections":{"analysis":[{"id":"section-1","level":2,"title":"TKI-first treatment was favored despite the absence of an overall-survival difference at the time"},{"id":"section-2","level":2,"title":"Timely, interpretable genotyping was treated as a prerequisite for safe treatment selection"},{"id":"section-3","level":2,"title":"Modern intensification preferences were conditional, while predictive selection remained unresolved"},{"id":"section-4","level":2,"title":"Supportive care was integral to the amivantamab option, with anticoagulation duration still questioned"},{"id":"section-5","level":2,"title":"CNS control favored systemic treatment first, but selective local-treatment roles were retained"},{"id":"section-6","level":2,"title":"Historical-control questions exposed unresolved disagreement about mutation-associated prognosis"},{"id":"section-7","level":2,"title":"The common-mutation treatment discussion did not translate into a single approach for uncommon sensitizing mutations"},{"id":"section-8","level":2,"title":"European confirmation was viewed as an access-enabling step, not merely replication of Asian findings"},{"id":"section-9","level":2,"title":"Retrospective commentary emphasized population selection and the provisional nature of clinical understanding"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3"},"identity":{"accepted_at":"2026-10-08T03:47:17.775241Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-07T22:54:07Z","record_hash":"a086e82e15f5a0c3a02db2c812063205c994ad2612010d07d0a19a358b89c5a6","release_hash":"b75a07513c2f776240bd399fa7584154ee130c4a28e893ad5b81df97f9204552","report_id":"erudio-nct00446225","run_id":"3d7e5b88-9baf-4b1e-a46a-d2ee59e51e1f","schema_version":"5.0","slug":"eurtac-00446225","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"EURTAC frames a clinician question: should erlotinib or chemotherapy be the initial treatment for advanced non-small cell lung cancer with activating EGFR mutations? Discussion topics include survival interpretation after crossover, historical comparisons, molecular testing, population applicability and reimbursement. Connected treatment questions cover selection among newer regimens, whether and when to intensify therapy, brain metastases and radiotherapy, uncommon mutations, toxicity prevention, specialist referral and administration burden. The account draws on retained public clinician commentary.","meta_description":"12 HCP sources screened · 210 verified claims from 9 sources · 9 findings. Updated 2026-10-08.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-405d998ce3d488f628b2","claim-3643e38ec8547fe9a062"],"id":"F6","paraphrase":"An audience participant in a YouTube discussion asked whether historical chemotherapy-only groups could establish a survival advantage for erlotinib without EURTAC’s direct comparison. A follow-up question requested numbers for the survival comparison.","source_channel":"youtube","source_date":"2012-10-12","title":"Historical-control questions exposed unresolved disagreement about mutation-associated prognosis"},{"cited_claim_ids":["claim-3325870372d772b59347","claim-42a631168521561ec144"],"id":"F4","paraphrase":"An audience participant in a YouTube panel asked when anticoagulation could end for patients taking amivantamab together with lazertinib. Another speaker asked whether anticoagulation should always accompany treatment that does not include amivantamab.","source_channel":"youtube","source_date":"2024-09-07","title":"Supportive care was integral to the amivantamab option, with anticoagulation duration still questioned"}]},"publication":{"approved_at":"2026-10-07T22:54:07Z","approved_by":"Audun Utengen","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"1.0","scope_and_limits":{"commentary_scope":{"basis":"Reviewed retained sources only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"held_out_finds":5,"refresh_due_at":"2026-10-09T03:47:17.775241Z","retrieval_gaps":["commentary:coverage_scope:keyword matches to trial identifier and registry aliases; single-letter acronym variants require planned context in the same indexed chunk; unnamed references or other transcription variants may be absent","commentary:indexed_source_unreadable:youtube:video_id:47AMiNyJBl4:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:9bQBr3oKByw:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:a1733NRnLvw:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:vCyfMIB1s8M:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:source_uncertainty:mcp:podcast:a72709@43374:44823: The source labels the speaker in UNIT_4 as unidentified; no source-native name is available for this turn. Keep the skin-toxicity practice claims unnamed and do not attach a profile.","commentary:held_out:mcp:youtube:s6nqYhVgP7E@54706:54899,mcp:youtube:s6nqYhVgP7E@50905:52651,mcp:youtube:s6nqYhVgP7E@4210:6242: a claim treats the referents of Luis's “those two combinations” as unresolved, although the connected question in mcp:youtube:s6nqYhVgP7E@50905:52651 explicitly identifies FLAURA-2 and ami-laz. mcp:youtube:s6nqYhVgP7E@4210:6242 supplies the osimertinib-plus-chemotherapy comparison. The report repeats this false ambiguity, obscuring the target of Luis's favorable view and intended practice.","commentary:held_out:mcp:youtube:s6nqYhVgP7E@57708:58264,mcp:youtube:s6nqYhVgP7E@58338:58726,mcp:youtube:s6nqYhVgP7E@57162:57706: a claim states an anticoagulation recommendation for “all patients” without retaining its regimen-specific scope. The respondent is answering mcp:youtube:s6nqYhVgP7E@57162:57706's question about lazertinib plus amivantamab; mcp:youtube:s6nqYhVgP7E@58338:58726 then separately asks whether anticoagulation should always be used without amivantamab. The exported claim therefore risks turning a combination-specific recommendation into universal prophylaxis."],"source_count":12,"unreadable_unit_ids":[]},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.","1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.","5 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.","4 further source limits are recorded in the machine-readable scope of this record.","The reviewed public material is not representative of all HCPs. Some recordings were unavailable, and discussions using unnamed or variant references to the trial may be missing.","Publication and upload dates do not establish the exact session or readout date. They also do not demonstrate a change of mind across settings.","Similar content in separate recordings is not counted as independent HCP agreement. Source-native names are retained, and unnamed passages are not assigned to roster participants.","Several survival statements concern the reporting time and crossover interpretation rather than the final status of all later EURTAC analyses.","Approximate or inconsistent numbers remain what speakers said. Bossaer's 0.037 European-study hazard ratio lacks an endpoint in the passage, and his iPASS account explicitly says the 0.48 estimate followed exclusion of EGFR-mutated patients.","Historical approval, access and dosing statements are not current guidance, and individual prophylaxis or toxicity-management practices are not universal protocols.","The original protocol and some linked full-text or regulatory material were unavailable, limiting how completely the underlying evidence can resolve questions raised in the commentary.","The report retains the separate Chinese-study early-use interpretation but does not label that study's estimates as EURTAC results."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":2,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":9},"count":9,"evidence_window":{"end":"2026-01-15","start":"2010-10-13"},"retrieval_snapshot":"2026-10-08T03:28:43.527913Z","timeline":[{"count":1,"week":"2010-W41"},{"count":1,"week":"2011-W26"},{"count":1,"week":"2012-W16"},{"count":1,"week":"2012-W41"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W15"},{"count":1,"week":"2024-W19"},{"count":1,"week":"2024-W36"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2026-W03"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT00446225:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT00446225:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT00446225:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:22285168","quote_policy":"short_quote_link_out"},{"id":"pubmed:24493829","quote_policy":"short_quote_link_out"},{"id":"pubmed:25806291","quote_policy":"short_quote_link_out"},{"id":"pubmed:26181014","quote_policy":"short_quote_link_out"},{"id":"openfda:4c89cedc-e48b-445c-ad05-54dbe60e4fb0:20260721","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:36d0b4","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a72709","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1631653708768612353:220738c0-59fd-45e7-aedd-c3852da765fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1644817610289172484:33d6d7e2-d62a-4fc1-a84b-1efb23338a64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1789366598089785534:6c080975-a710-4ae6-9bb7-2f54d69b282b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1930635381667664184:b8e6c864-0621-4145-a6ee-56a51a9bc217","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:872147701231759364:e42d8270-ef88-4980-b565-bd447f15c392","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:8mCa5R2k7Eg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:EgmCFoJPd7c","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ljld1FCSC5o","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:s6nqYhVgP7E","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:vQQhmfAQnrk","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":12},"count":12,"evidence_window":{"end":"2026-01-15","start":"2010-10-13"},"retrieval_snapshot":"2026-10-08T03:28:43.527913Z","timeline":[{"count":1,"week":"2010-W41"},{"count":1,"week":"2011-W26"},{"count":1,"week":"2012-W16"},{"count":1,"week":"2012-W41"},{"count":1,"week":"2017-W23"},{"count":1,"week":"2023-W09"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W15"},{"count":1,"week":"2024-W19"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W36"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2025-W23"},{"count":1,"week":"2026-W03"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: erlotinib","status":"unmapped"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"reason":"Unmapped registry intervention: gemcitabin","status":"unmapped"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"EURTAC","aliases":["EURTAC","Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR","Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR"],"brief_title":"Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":174,"type":"ACTUAL"},"excluded_lookalike_trials":{"reason":"No owner-reviewed lookalike exclusion list.","status":"not_set"},"interventions":[{"name":"Erlotinib","synonyms":["Tarceva"],"type":"DRUG"},{"name":"Carboplatin","synonyms":["Paraplatin"],"type":"DRUG"},{"name":"Gemcitabin","synonyms":["Gemzar"],"type":"DRUG"},{"name":"Docetaxel","synonyms":["Taxotere"],"type":"DRUG"},{"name":"Cisplatin","synonyms":["Platinol"],"type":"DRUG"}],"nct_id":"NCT00446225","official_title":"Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2012-04-11","type":"ACTUAL"},"primary_endpoints":[{"description":"The time from enrollment in the study to tumor progression or death from any cause (whichever occurs first)","measure":"Progression Free-survival","timeFrame":"From the date of randomization to the date of last follow up, assessed up to 24 months"}],"registry_last_updated":"2025-03-05","registry_url":"https://clinicaltrials.gov/study/NCT00446225","short_name":"EURTAC","short_name_basis":"registry_acronym","sponsor":"Spanish Lung Cancer Group","start_date":{"date":"2007-02-15","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"EURTAC-SLCG // GECP06/01","type":"sponsor_study_id"},{"id":"2006-003568-73","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}